drugset
drugset / Trial / NCT04797793

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793 ↗

Phase 0 Completed 978 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.

Timeline

Start
2020-05-18
Primary completion
2021-01-08
Completion
2021-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adapalene Other / unclassified 0.1 % Topical

Indications

acne